The use of adeno-associated virus to circumvent the maturation-dependent viral transduction of muscle fibers.

Muscle-based gene therapy using adenovirus, retrovirus, and herpes simplex virus has been hindered by viral cytotoxicity, host immune response, and the maturation-dependent viral transduction of muscle fibers. The development of new mutant vectors has greatly reduced the toxicity and the immune rejection problems, but the inability of viral vectors to penetrate and transduce mature myofibers remains an important issue. Research has been focused on the characterization of barriers to viral transduction in mature myofibers to develop strategies to circumvent the maturation-dependent viral transduction of myofibers. Here, we report that adeno-associated virus (AAV) can be used to overcome the maturation-dependent viral transduction of myofibers. We have investigated by which mechanism AAV can penetrate and efficiently transduce mature muscle fibers, and have shown that this viral vector is not blocked by the basal lamina and that AAV transduction of myofibers is independent of myoblast mediation. Although AAV can efficiently transduce mature myofibers, a differential transduction is still observed among the different types of myofibers that correlates with the expression of the heparan sulfate proteoglycan receptors, the muscle maturity, the number of viral particles used, and the time postinjection. The identification of the mechanisms by which AAV transduces mature myofibers will help in the development of strategies to achieve an efficient muscle-based gene therapy for inherited and acquired diseases.

[1]  Jian Liu,et al.  Cell surface heparan sulfate and its roles in assisting viral infections , 2002, Medicinal research reviews.

[2]  S. Ylä-Herttuala,et al.  Gene therapy for therapeutic angiogenesis in critically ischaemic lower limb – on the way to the clinic , 2001, European journal of clinical investigation.

[3]  C. Emanueli,et al.  Angiogenesis gene therapy to rescue ischaemic tissues: achievements and future directions , 2001, British journal of pharmacology.

[4]  P. Moisset,et al.  Gene therapy: a strategy for the treatment of inherited muscle diseases? , 2001, Current opinion in pharmacology.

[5]  Juan Li,et al.  Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[6]  R. Samulski,et al.  Adeno-associated virus vectors for gene therapy: more pros than cons? , 2000, Molecular medicine today.

[7]  S. Wilton,et al.  Gene therapy and molecular approaches to the treatment of hereditary muscular disorders , 2000, Current opinion in neurology.

[8]  R. Balice-Gordon,et al.  Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector , 1999, Nature Medicine.

[9]  A. Musarò,et al.  Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Freddie H. Fu,et al.  Development of approaches to improve the healing following muscle contusion. , 1998, Cell transplantation.

[11]  J. Glorioso,et al.  Implications of maturation for viral gene delivery to skeletal muscle , 1998, Neuromuscular Disorders.

[12]  E. Hoffman,et al.  Muscle maturation: implications for gene therapy. , 1998, Molecular medicine today.

[13]  G. Dickson,et al.  Effective restoration of dystrophin‐associated proteins in vivo by adenovirus‐mediated transfer of truncated dystrophin cDNAs , 1998, FEBS letters.

[14]  R. Samulski,et al.  Production of High-Titer Recombinant Adeno-Associated Virus Vectors in the Absence of Helper Adenovirus , 1998, Journal of Virology.

[15]  R. Samulski,et al.  Membrane-Associated Heparan Sulfate Proteoglycan Is a Receptor for Adeno-Associated Virus Type 2 Virions , 1998, Journal of Virology.

[16]  L. Kunkel,et al.  The fate of individual myoblasts after transplantation into muscles of DMD patients , 1997, Nature Medicine.

[17]  Simon C Watkins,et al.  Gene transfer to muscle using herpes simplex virus-based vectors , 1997, Neuromuscular Disorders.

[18]  S. Li,et al.  Selection and use of ligands for receptor-mediated gene delivery to myogenic cells , 1997, Gene Therapy.

[19]  X. Liang,et al.  Spatial–temporal patterns of gene expression in mouse skeletal muscle after injection of lacZ plasmid DNA , 1997, Gene Therapy.

[20]  Philip R. Johnson,et al.  Recombinant adeno-associated viral vectors mediate long-term transgene expression in muscle. , 1997, Human gene therapy.

[21]  J. Tremblay,et al.  Control of inflammatory damage by anti-LFA-1: increase success of myoblast transplantation. , 1997, Cell transplantation.

[22]  Simon C Watkins,et al.  LacZ gene transfer to skeletal muscle using a replication-defective herpes simplex virus type 1 mutant vector. , 1997, Human gene therapy.

[23]  Simon C Watkins,et al.  Viral gene delivery to skeletal muscle: insights on maturation-dependent loss of fiber infectivity for adenovirus and herpes simplex type 1 viral vectors. , 1997, Human gene therapy.

[24]  James M. Wilson,et al.  Recombinant adeno-associated virus for muscle directed gene therapy , 1997, Nature Medicine.

[25]  W. Gonyea,et al.  Effect of radiation on satellite cell activity and protein expression in overloaded mammalian skeletal muscle , 1997, The Anatomical record.

[26]  B. Byrne,et al.  Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Simon C Watkins,et al.  The basal lamina is a physical barrier to herpes simplex virus-mediated gene delivery to mature muscle fibers , 1996, Journal of virology.

[28]  R. Samulski,et al.  Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector , 1996, Journal of virology.

[29]  R. Roy,et al.  Immunosuppression with monoclonal antibodies and CTLA4-Ig after myoblast transplantation in mice. , 1996, Transplantation.

[30]  A. Mcshea,et al.  Adenoviral-mediated overexpression of I(kappa)B(alpha) in endothelial cells inhibits natural killer cell-mediated endothelial cell activation. , 1996, Transplantation.

[31]  R. Balice-Gordon,et al.  In vivo expression of full-length human dystrophin from adenoviral vectors deleted of all viral genes. , 1996, Human gene therapy.

[32]  J. Chamberlain,et al.  Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cells. , 1996, Human molecular genetics.

[33]  C. Caskey,et al.  A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[34]  D. Russell,et al.  Effects of gamma irradiation on the transduction of dividing and nondividing cells in brain and muscle of rats by adeno-associated virus vectors. , 1996, Human gene therapy.

[35]  L. Vitiello,et al.  Condensation of plasmid DNA with polylysine improves liposome-mediated gene transfer into established and primary muscle cells. , 1996, Gene therapy.

[36]  G. Breese,et al.  Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector , 1996, Brain Research.

[37]  Hanns Lochmüller,et al.  Dystrophin expression in muscles of mdx mice after adenovirus-mediated in vivo gene transfer. , 1996, Human gene therapy.

[38]  C. Gravel,et al.  FK506 immunosuppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer. , 1995, Human gene therapy.

[39]  R. R. Rice,et al.  Myoblast transfer in the treatment of Duchenne's muscular dystrophy. , 1995, The New England journal of medicine.

[40]  G. Trinchieri,et al.  Recombinant IL–12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung , 1995, Nature Medicine.

[41]  T. Flotte,et al.  Adeno-associated virus vectors for gene therapy. , 1995, Gene therapy.

[42]  R. Linden,et al.  The cryptic life style of adenoassociated virus , 1995, BioEssays : news and reviews in molecular, cellular and developmental biology.

[43]  T. Flotte,et al.  Adeno-associated virus vector gene expression occurs in nondividing cells in the absence of vector DNA integration. , 1994, American journal of respiratory cell and molecular biology.

[44]  David W. Russell,et al.  Adeno-associated virus vectors preferentially transduce cells in S phase. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[45]  G. Acsadi,et al.  Gene transfer into skeletal muscles by isogenic myoblasts. , 1994, Human gene therapy.

[46]  G. Acsadi,et al.  A differential efficiency of adenovirus-mediated in vivo gene transfer into skeletal muscle cells of different maturity. , 1994, Human molecular genetics.

[47]  B. Demeneix,et al.  Plasmid DNA is superior to viral vectors for direct gene transfer into adult mouse skeletal muscle. , 1993, Human gene therapy.

[48]  P. Tonali,et al.  Retroviral vector-mediated gene transfer into human primary myogenic cells leads to expression in muscle fibers in vivo. , 1993, Human gene therapy.

[49]  M. Perricaudet,et al.  Long–term correction of mouse dystrophic degeneration by adenovirus–mediated transfer of a minidystrophin gene , 1993, Nature genetics.

[50]  George Karpati,et al.  Myoblast transfer in duchenne muscular dystrophy , 1993, Annals of neurology.

[51]  B. Demeneix,et al.  Direct gene transfer into skeletal muscle in vivo: factors affecting efficiency of transfer and stability of expression. , 1993, Human gene therapy.

[52]  C. Richards,et al.  Results of a Triple Blind Clinical Study of Myoblast Transplantations without Immunosuppressive Treatment in Young Boys with Duchenne Muscular Dystrophy , 1993, Cell transplantation.

[53]  P. Briand,et al.  Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice , 1993, Nature.

[54]  R. Samulski.  Adeno-associated virus: integration at a specific chromosomal locus. , 1993, Current opinion in genetics & development.

[55]  T. Flotte,et al.  Gene expression from adeno-associated virus vectors in airway epithelial cells. , 1992, American journal of respiratory cell and molecular biology.

[56]  G. Acsadi,et al.  Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. , 1992, Human molecular genetics.

[57]  J. Mandel,et al.  Adenovirus as an expression vector in muscle cells in vivo. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[58]  K. Davies,et al.  Retroviral‐mediated transfer of a dystrophin minigene into mdx mouse myoblasts in vitro , 1992, FEBS letters.

[59]  J. Leiden,et al.  Systemic delivery of recombinant proteins by genetically modified myoblasts. , 1991, Science.

[60]  H. Blau,et al.  Systemic delivery of human growth hormone by injection of genetically engineered myoblasts. , 1991, Science.

[61]  K. Davies,et al.  Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs , 1991, Nature.

[62]  S. Lehnert,et al.  Major Alteration of the Pathological Phenotype in Gamma Irradiated mdx Soleus Muscles , 1991, Journal of neuropathology and experimental neurology.

[63]  C. Cametti,et al.  Dose-dependent effects of ionizing radiation on in vitro myoblast fusion. , 1990, International journal of radiation biology.

[64]  A. Miller,et al.  Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection , 1990, Molecular and cellular biology.

[65]  P. Yurchenco,et al.  Assembly of Basement Membranes a , 1990, Annals of the New York Academy of Sciences.

[66]  L. Kunkel,et al.  Conversion of mdx myofibres from dystrophin-negative to -positive by injection of normal myoblasts , 1989, Nature.

[67]  E. Ricci,et al.  Normal and dystrophin-deficient muscle fibers in carriers of the gene for Duchenne muscular dystrophy. , 1988, The American journal of pathology.

[68]  Simon C Watkins,et al.  Immunoelectron microscopic localization of dystrophin in myofibres , 1988, Nature.

[69]  Hideo Sugita,et al.  Immunostaining of skeletal and cardiac muscle surface membrane with antibody against Duchenne muscular dystrophy peptide , 1988, Nature.

[70]  R. Hodges,et al.  The Duchenne muscular dystrophy gene product is localized in sarcolemma of human skeletal muscle , 1988, Nature.

[71]  G. Butler-Browne,et al.  A developmentally regulated disappearance of slow myosin in fast‐type muscles of the mouse , 1984, FEBS letters.

[72]  P. Clemens,et al.  Progress in gene therapy for Duchenne muscular dystrophy , 2001, Current neurology and neuroscience reports.

[73]  Jacques Menetrey,et al.  Growth factors improve muscle healing in vivo , 2000 .

[74]  D. Dressman,et al.  rAAV vector-mediated sarcogylcan gene transfer in a hamster model for limb girdle muscular dystrophy , 1999, Gene Therapy.

[75]  Donald W. Pfaff,et al.  Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain , 1994, Nature Genetics.

[76]  N. Muzyczka.  Use of adeno-associated virus as a general transduction vector for mammalian cells. , 1992, Current topics in microbiology and immunology.

[77]  Eric P. Hoffman,et al.  Dystrophin: The protein product of the duchenne muscular dystrophy locus , 1987, Cell.

[78]  K. Berns,et al.  Adeno-associated viruses: an update. , 1987, Advances in virus research.